-
-
Call more information
660-596-2224 -
The FDA has approved Eloctate, a new prophylactic treatment for children and adults with hemophilia A. The infusion is long-acting and will decrease the number of doses required, with an infusion needed every 3 to 5 days (rather than three times weekly or every other day). Eloctate consists of the coagulation factor VIII molecule linked […]
Read MoreThe U.S. uninsured rate held steady at a record low of 13.4 percent in May, according to a recent Gallup poll. The uninsured rate appears to have leveled off after monthly declines in the wake of the Patient Protection and Affordable Care Act’s major provisions taking effect. It remains to be seen whether the uninsured […]
Read MoreHospitals across the country are struggling to deal with a shortage of one of their essential medical supplies. Manufacturers are rationing saline — a product used all over the hospital to clean wounds, mix medications and treat dehydration. Now drug companies say they won’t be able to catch up with demand until next year. That […]
Read MoreAuthors: Al-Khatib SM et al., JAMA 2014 Jun 4; 311:2209 In a cross-registry cohort of patients with LVEFs between 30% and 35%, mortality was significantly lower in those who received a device than in those who did not. Randomized controlled trials (RCTs) of implantable cardioverter-defibrillators (ICDs) in patients with cardiomyopathies have generally restricted enrollment to […]
Read MoreIn a cross-registry cohort of patients with left-ventricular ejection fractions between 30% and 35%, mortality was significantly lower in those who received a device than in those who did not. The findings were published in JAMA.
Read More